Estrogenic Effect-Based Monitoring

Under Art 8a(3) of Directive (EU) 2026/805, Member States must apply effect-based monitoring methods for estrogenic substances (EE2 No.46, E2 No.47, and E1 No.59) for at least 2 years from 1 January 2030. Effect-based methods detect the combined estrogenic activity of all compounds in a sample (not just the three listed), providing a more sensitive and comprehensive assessment. Exceedance of an 'effect-based trigger value' triggers further investigation.